What Does Sanofi ($SNY) Do? - Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
Sanofi (SNY) is a global large-cap pharmaceutical company headquartered in France, operating Specialty Care, Vaccines, and General Medicines businesses. Dupixent revenue growth and the global vaccines franchise anchor its top line, and the stock is classified as a core dividend payer in the healthcare sector.
Subscribe🏢 What kind of company is Sanofi?
Sanofi (SNY) is the U.S.-listed ADR of a global large-cap pharmaceutical company headquartered in France. Built through a long history of mergers and acquisitions, the group has assembled a broad portfolio spanning multiple therapeutic areas—including immunology & inflammation, rare diseases, and vaccines—positioning it as a diversified pharmaceutical group.
Its operations are organized into Specialty Care (immunology & inflammation, rare diseases, oncology), Vaccines (influenza, respiratory, and pediatric vaccines), and General Medicines. The Specialty Care franchise, anchored by Dupixent, and the global vaccines business serve as the core revenue engines.
How does Sanofi make money?| Business Segment | Revenue Weight | Description |
|---|---|---|
| Specialty Care | Core | High-value therapies including Dupixent, rare disease, and oncology products |
| Vaccines | Key growth engine | Global supply of influenza, respiratory, and pediatric vaccines |
Specialty Care accounts for the largest share of revenue, and Dupixent's sales growth drives the group's overall growth trajectory. The Vaccines segment delivers a stable revenue base anchored by global supply of influenza and respiratory vaccines, while the General Medicines segment sustains a steady stream of prescription sales. This diversified mix has gradually lowered dependence on any single product, and R&D investment continues at a steady pace.
📐 Sanofi's market cap and corporate scale
Its market cap stands at $99.2B and the company employs 76,493 people people.
It is a diversified pharmaceutical group ranked among the top-tier global large-cap pharma names by market cap. It is benchmarked against other major pharmaceutical groups such as PFE, MRK, and JNJ, with the weight of its Specialty Care and Vaccines businesses serving as points of differentiation. Backed by a stable dividend policy, it is classified as a global healthcare core dividend stock, balancing R&D investment with capital return to shareholders.
📈 Sanofi's outlook and stock performance
1-Year Price Performance
Analyst Consensus
52-Week Price RangeDupixent label expansions and a new immunology & inflammation pipeline are the key medium- to long-term growth drivers. Expansion in the respiratory vaccines area and the strengthening of the rare disease portfolio also serve as diversification pillars, while portfolio reshaping continues through a combination of in-house R&D and external licensing. Near-term volatility factors include the patent expiration cycle for some key products, changes in global drug pricing policy, and the impact of FX translation on reported revenue. Clinical trial readouts for pipeline candidates and the regulatory environment should also be monitored.
- Dupixent label expansions and sales growth
- Expansion in respiratory and pediatric vaccines
- Strengthening of the Specialty Care portfolio across rare diseases and oncology